Peptide Series Part 2: Growth Hormone Secretagogues and How They Fit into Health Optimization
This is the second article in the Paradigm Health peptide series. In Part 1, the focus was on repair and recovery peptides like BPC‑157, TB‑500, GHK‑Cu, and KPV. This installment turns to a different but complementary lever: growth hormone secretagogues (GHS) and how they can be used physiologically to support body composition, recovery, and healthy aging.
GH secretagogues vs synthetic GH
Classic GH replacement uses exogenous recombinant GH. That approach bypasses the hypothalamic–pituitary axis and can produce non‑physiologic, flat exposure with more potential for fluid retention, insulin resistance, and IGF‑1 overshoot. Growth hormone secretagogues instead signal the pituitary to release endogenous GH, preserving the normal feedback systems and pulsatile pattern of secretion.
Two main receptor systems are involved:
GHRH receptor (Growth Hormone–Releasing Hormone) – targeted by GHRH analogs like Sermorelin, CJC‑1295, and Tesamorelin.
Ghrelin (GHS‑R1a) receptor – targeted by ghrelin mimetics like Ipamorelin and other GHRPs.
Using these pathways, GH secretagogues can increase GH and downstream IGF‑1 in a way that is closer to youthful physiology and can be more easily cycled and titrated.
The four key GH secretagogues in practice
1. Sermorelin – why it is usually the best place to start
Mechanism and physiology
Sermorelin is a synthetic analog of endogenous GHRH, binding to GHRH receptors in the anterior pituitary and triggering a normal GH pulse. It amplifies the body’s existing nocturnal pulses rather than forcing GH release at random times.
Magnitude of GH/IGF‑1 increase
In older adults, short‑ and long‑term studies show sermorelin can increase peak GH responses by 80–100% and roughly double mean nocturnal GH over 12–16 weeks, with IGF‑1 rising into the youthful reference range academic.
In GH‑deficient children, 6‑month sermorelin therapy significantly increased GH release and growth velocity vs baseline.
These are moderate, physiologic increases compared with very large spikes seen with some synthetic GHRPs. That profile is exactly why it is often the first‑line peptide in a GH‑axis protocol.
Why Sermorelin is usually the starting point:
It uses the native GHRH receptor, preserving normal hypothalamic feedback and pulsatility.
It has a shorter half‑life than CJC‑1295 or Tesamorelin, making it more controllable and easier to stop or adjust quickly if IGF‑1 rises too high or side effects appear.
Clinical data suggest sustained benefits even after stopping (IGF‑1 remains above baseline for weeks), indicating a “reconditioning” of the axis rather than pure on/off pharmacology.pmc.ncbi.nlm.nih
For a wellness/longevity population rather than severe deficiency, this combination of safety, physiologic signaling, and moderate efficacy makes sermorelin the rational place to start.
2. Ipamorelin – a selective ghrelin mimetic for bigger pulses
Mechanism
Ipamorelin is a selective agonist of the GHS‑R1a (ghrelin) receptor on pituitary growth signaling cells. It stimulates GH release in a way that mimics endogenous ghrelin, but with far greater selectivity than older GHRPs (e.g., minimal effect on prolactin or cortisol).
Magnitude of GH increase
Experimental data show that Ipamorelin exposure can increase GH concentrations many‑fold (reports of >60‑fold vs placebo in some research settings), reflecting very strong pulse
Unlike some GHRPs, its selectivity reduces off‑target hormonal stimulation.
In clinical protocols, ipamorelin is often combined with a GHRH analog (sermorelin or CJC‑1295) to create a “double hit”: GHRH receptor activation plus ghrelin receptor activation. This dual signaling tends to generate higher GH peaks and more robust IGF‑1 elevation than either alone.
3. CJC‑1295 – long‑acting GHRH analog for baseline support
CJC‑1295 is a modified GHRH analog engineered for prolonged half‑life through albumin binding. A single injection can elevate GH and IGF‑1 for days.
Pulsatility and magnitude
A pivotal study in healthy men found that after a single CJC‑1295 dose:
Basal (trough) GH increased ~7.5‑fold.
Mean GH over 12 hours increased ~46%.
IGF‑1 increased ~45%.
Importantly, GH pulse frequency and amplitude were preserved – the pulses ride on a higher baseline rather than being flattened.
When combined with Ipamorelin, CJC‑1295 provides the “background” and Ipamorelin the sharp spikes. This stack is now one of the most commonly used GH‑axis research combinations for more aggressive GH restoration.
4. Tesamorelin – the most studied GHRH analog
Tesamorelin is a stabilized 44‑amino‑acid GHRH analog, made resistant to enzymatic breakdown, with a longer half‑life than native GHRH.
Evidence and magnitude
FDA‑approved in 2010 for HIV‑associated lipodystrophy, with at least five pivotal RCTs.
Trials show tesamorelin significantly reduces visceral adipose tissue in HIV patients and increases IGF‑1 by roughly 100 ng/mL on average.
It improves body composition and hepatic fat content without major deterioration in glucose control in this population.
Outside of HIV lipodystrophy, tesamorelin provides a higher potency GHRH analog with a strong evidence base, and it can be considered in more advanced cases where moderate approaches (e.g., sermorelin alone) are insufficient and risk/benefit is acceptable.
IGF‑1: how and why it is used in monitoring
IGF‑1 is the primary downstream marker of GH action and is the most practical lab to monitor response and safety during peptide-based GH modulation.pmc.ncbi.nlm.nih+1
Key points for practice:
Baseline IGF‑1 is sometimes obtained before starting a GH secretagogue cycle and definitely before repeating a cycle.
During therapy, IGF‑1 should move into an upper‑normal, age‑adjusted range, not a supraphysiologic bodybuilder range.
IGF‑1 is usually checked every 12 weeks during a new protocol or dose change, then at longer intervals once a stable pattern is established, similar to GH‑replacement guidelines.
Persistently high IGF‑1 (above normal) is a signal to reduce dose, alter frequency, or shorten cycles.
In summary, IGF‑1 becomes the “speedometer” for cyclical use of sermorelin/ipamorelin/ CJC‑1295/tesamorelin – guiding how aggressive a cycle can be and when it is time to back off.
But, there is more to IGF-1 and why physician oversight of your peptide program with careful personalization makes sense. Chronically elevated IGF‑1 is associated with higher risk of several cancers, and the totality of human data supports a probable causal role in at least some tumor types—but the relationship is dose‑ and context‑dependent, and both very low and very high IGF‑1 appear harmful.
What the human data show
Large prospective cohorts and Mendelian randomization work have moved the IGF‑1 story beyond simple association.
A UK Biobank analysis of ~400,000 participants found that higher circulating IGF‑1 was associated with increased risk of several cancers, confirming prior links with colorectal, breast, and prostate cancer and suggesting additional associations (thyroid, myeloma, melanoma), while not all cancers showed a clear relationship.
A 2020 analysis of IGF‑1 and risk of 19 site‑specific cancers reported that each 5 nmol/L increase in IGF‑1 was associated with a modest increase in total cancer risk and specific increases for breast, prostate, colorectal, kidney, and thyroid cancers; intriguingly, higher IGF‑1 was associated with lower risk of lung, ovarian, and liver cancer, highlighting tissue‑specific effects.
A 2023 J Clin Endocrinol Metab study showed a U‑shaped relationship between IGF‑1 and mortality: both the lowest and highest IGF‑1 quintiles had higher all‑cause, cardiovascular, and cancer mortality compared with mid‑range values.
Taken together, these data strongly support the idea that chronically elevated IGF‑1 is not benign, especially when far above age‑adjusted physiologic ranges.
Association vs causation
Mechanistically, IGF‑1 is exactly the kind of molecule you would worry about in cancer biology:
It promotes cell proliferation and survival and inhibits programmed cell death (apoptosis) via several important pathways.
The IGF‑1/IGF‑1R system is now regarded as an “important promoter of tumor growth and progression” in multiple cancers and is a target of ongoing drug development.
Epidemiologically:
Early observational work already showed that high serum IGF‑1 is associated with increased risk of breast, prostate, colorectal, and lung cancers.
More recent Mendelian randomization analyses (e.g., for ER‑positive breast cancer) show that genetically higher IGF‑1 (i.e., lifelong exposure) increases risk, which is much harder to explain away as reverse causality; these studies conclude that elevated IGF‑1 is probably causal for at least some breast cancer subtypes.
So from a modern evidentiary standpoint:
For some cancers (notably breast and prostate), the IGF pathway is very likely part of the causal architecture, not just an innocent bystander.academic.
That does not mean a transient, modest increase into the upper‑normal range during monitored therapy equals “causing cancer,” but it does mean that chronic supraphysiologic IGF‑1 is a plausible cancer‑promoting environment, especially in susceptible tissues.
How this should guide clinical practice
For longevity‑oriented use of GH secretagogues/peptides:
Aim for age‑appropriate mid‑to‑upper‑normal IGF‑1, not sustained supraphysiologic levels. The U‑shaped mortality data argue against both low and very high values.
Use periodic monitoring of IGF‑1 and adjust dose/cycle lengths to avoid sustained elevations above the reference range.
More conservative in patients with strong personal or family histories of hormone‑sensitive cancers, and avoid any attempt to “push” IGF‑1 into bodybuilder ranges for aesthetics or performance.
Emphasize that IGF‑1 is one of many growth‑signaling inputs (insulin, mTOR, inflammatory cytokines, etc.), and that the global terrain (dietary pattern, insulin levels, adiposity, inflammation)is at least as important as the peptide itself.
Elevated IGF‑1 is clearly associated with higher risk of several cancers, and for some, the evidence supports a causal contribution. In practice, that argues for physiologic restoration and cyclical use with careful monitoring, not sustained pharmacologic elevation.
Insulin, GH, nighttime dosing, and the “no late eating” rule
GH and insulin are deeply intertwined in metabolic regulation. In the fed (post-eating), hyperinsulinemic state, insulin promotes glucose storage and suppresses lipolysis (fat breakdown); GH exerts the opposite effect in the fasting state, promoting lipolysis and preserving glucose. Chronic hyperinsulinemia and elevated FFAs, as in obesity and insulin resistance, are associated with reduced endogenous GH secretion.
Practical implications for peptide use:
GH pulses are naturally largest at night, especially soon after sleep onset.
Eating close to bedtime raises insulin and shifts the metabolic environment toward storage mode, the opposite of what GH is trying to do.
Increased FFAs, insulin, and free IGF‑1 are all signals that, over time, suppress pituitary GH output.
Accordingly, Paradigm Health protocols recommend:
Dosing GH secretagogues in the evening, typically 30–60 minutes before bed, to synergize with naturally programmed GH pulses.
Avoiding caloric intake for 2–3 hours before dosing, so that insulin and glucose are trending down and the peptide can augment the endogenous nighttime GH surge rather than fighting against a fed, insulin‑dominant state.
The physiology here aligns with both GH biology and metabolic goals: you want GH signaling in a relatively fasted, low‑insulin window.
Expected timeline of benefits
Patients often ask: “When will I feel this?” GH‑axis modifications are slow medicine, especially when done physiologically.
Based on GH/GHS literature and clinical experience:
Weeks 2–4
Improvements in sleep depth and recovery.
Subtle changes in morning energy, mood, and exercise tolerance.
Months 2–3
Noticeable improvements in exercise recovery, DOMS, and joint resiliency.
Early body composition changes: slightly less central fat, small increases in lean mass, better skin texture/elasticity.pure.
Months 3–6 and beyond
Clearer increases in lean body mass and strength, especially when combined with resistance training and adequate protein.
Continued reduction in visceral and subcutaneous fat, improved waist circumference, and often better glycemic and lipid profiles in parallel lifestyle programs.pure.
Subjective improvements in vitality, cognitive clarity, and overall resilience.
These are typical ranges; individual responses vary based on age, baseline GH/IGF‑1, insulin sensitivity, training, sleep, and the exact peptide combination.
Positioning within a Paradigm Health plan
Within the health optimization framework that we practice at Paradigm, GH secretagogues are tools, not magic bullets. They make the physiology more favorable for muscle retention, fat loss, and tissue repair – but they work best when layered on top of:
Nutritional strategies that protect insulin sensitivity.
Resistance training and appropriate aerobic work.
Sleep optimization and stress management.
From there, the sequence looks roughly like:
Start with sermorelin at night, in fasting window; establish response and IGF‑1 trajectory.
Consider adding ipamorelin or upgrading to a CJC‑1295/Ipamorelin stack for more robust GH pulses if needed, with close IGF‑1 monitoring.
Reserve tesamorelin for cases where a more potent, evidence‑rich GHRH analog is appropriate (e.g., significant visceral adiposity, complex metabolic phenotypes) and risk/benefit justifies it, recognizing its RCT‑level data set.
All of this is done cyclically, with IGF‑1 levels, body composition, and patient‑reported outcomes guiding duration and intensity of each cycle.